Hematopoietic cell transplantation (HCT) provides potentially curative treatment for patients
with myelofibrosis (MF). HCT outcomes are associated with the Dynamic International …

Abstract Studies by the International Working Group showed that the prognosis of
myelofibrosis patients is predicted by the Dynamic International Prognostic Scoring System …

Accurate prognostic tools are crucial to assess the risk/benefit ratio of allogeneic
hematopoietic cell transplantation (allo-HCT) in patients with myelofibrosis (MF). We aimed …

To develop a prognostic model for patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients …

Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for
myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF …

Background Myelofibrosis is a myeloproliferative stem cell disorder curable exclusively by
allogeneic hematopoietic stem cell transplantation and is associated with substantial …

Allogeneic hematopoietic stem cell transplantation (SCT) is the only curative option for
patients with primary myelofibrosis (PMF), but information on its net advantage over …

Allogeneic hematopoietic cell transplant (allo-HCT) remains the only potentially curative
therapeutic modality for patients with primary or secondary myelofibrosis (MF). However …

Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in
myelofibrosis in the early post-HCT period have not been defined thus far. We attempt to …

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for
myelofibrosis. Most post-transplantation events occur during the first two years and hence …